Clinical relevance of the bile acid receptor TGR5 in metabolism

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 3, 2017, Pages 224-233

  van Nierop, F Samuel ^a   Scheltema, Matthijs J ^a   Eggink, Hannah M ^a   Pols, Thijs W ^a   Sonne, David P ^b   Knop, Filip K ^b,c   Soeters, Maarten R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BILE ACID; BILE ACID SEQUESTRANT; CHENODEOXYCHOLIC ACID; COLESEVELAM; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; PEPTIDE YY; PLACEBO; SB 756050; SODIUM BILE ACID COTRANSPORTER; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; GPBAR1 PROTEIN, HUMAN; GPBAR1 PROTEIN, MOUSE;

BILE ACID METABOLISM; BROWN ADIPOSE TISSUE; CYTOKINE RELEASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENTEROHEPATIC CIRCULATION; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; POSTPRANDIAL STATE; REVIEW; ROUX-EN-Y GASTRIC BYPASS; THERMOGENESIS; ANIMAL; ENERGY METABOLISM; SECRETION (PROCESS);

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INFLAMMATION; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84994706873     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30155-3     Document Type: Review

References (101)

1. 1 Watanabe, M, Houten, SM, Mataki, C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006), 484–489.
2. 2 Thomas, C, Gioiello, A, Noriega, L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10 (2009), 167–177.
3. 3 Sato, H, Genet, C, Strehle, A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 362 (2007), 793–798.
4. 4 Maruyama, T, Tanaka, K, Suzuki, J, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 191 (2006), 197–205.
5. 5 Reimann, F, Gribble, F, G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia 59 (2016), 229–233.
6. 6 Hodge, R, Nunez, D, The Therapeutic potential of TGR5 agonists. Hope or hype?. Diabetes Obes Metab 18 (2016), 439–443.
7. 7 Kawamata, Y, Fujii, R, Hosoya, M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 278 (2003), 9435–9440.
8. 8 Maruyama, T, Miyamoto, Y, Nakamura, T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298 (2002), 714–719.
9. 9 Keitel, V, Donner, M, Winandy, S, Kubitz, R, Häussinger, D, Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372 (2008), 78–84.
10. 10 Poole, DP, Godfrey, C, Cattaruzza, F, et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 22 (2010), 814–825 e227–28.
11. 11 Brighton, CA, Rievaj, J, Kuhre, RE, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally-located G-protein coupled bile acid receptors. Endocrinology 156 (2015), 3961–3970.
12. 12 Kumar, DP, Rajagopal, S, Mahavadi, S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem Biophys Res Commun 427 (2012), 600–605.
13. 13 Pols, TWH, Nomura, M, Harach, T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14 (2011), 747–757.
14. 14 Vors, C, Pineau, G, Drai, J, et al. Postprandial endotoxemia linked with chylomicrons and lipopolysaccharides handling in obese versus lean men: a lipid dose-effect trial. J Clin Endocrinol Metab 100 (2015), 3427–3435.
15. 15 Alemi, F, Kwon, E, Poole, D, Lieu, T, The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 123 (2013), 1513–1530.
16. 16 Keitel, V, Reinehr, R, Gatsios, P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45 (2007), 695–704.
17. 17 Futatsugi, K, Bahnck, K, Brenner, M, et al. Optimization of triazole-based TGR5 agonists towards orally available agents. Med Chem Comm 4 (2013), 205–210.
18. 18 Kida, T, Tsubosaka, Y, Hori, M, et al. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol 33 (2013), 1663–1669.
19. 19 Thomas, C, Auwerx, J, Schoonjans, K, Bile acids and the membrane bile acid receptor TGR5-connecting nutrition and metabolism. Thyroid 18 (2008), 167–174.
20. 20 Duboc, H, Taché, Y, Hofmann, AF, The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 46 (2014), 302–312.
21. 21 Hofmann, AF, Hagey, LR, Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65 (2008), 2461–2483.
22. 22 LaRusso, N, Hoffman, N, Korman, M, Hofmann, AF, Cowen, A, Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J Dig Dis 23 (1978), 385–391.
23. 23 Sato, H, Macchiarulo, A, Thomas, C, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 51 (2008), 1831–1841.
24. 24 Lefebvre, P, Cariou, B, Lien, F, Kuipers, F, Staels, B, Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89 (2009), 147–191.
25. 25 Spinelli, V, Lalloyer, F, Baud, G, et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes, 2016, 10.1038/ijo.2016.46 published online Mar 22.
26. 26 Hardison, WG, Grundy, SM, Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology 84 (1983), 617–620.
27. 27 Bennion, LJ, Grundy, SM, Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 296 (1977), 1365–1371.
28. 28 Brufau, G, Stellaard, F, Prado, K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52 (2010), 1455–1464.
29. 29 Sonne, DP, van Nierop, FS, Kulik, W, Soeters, MR, Vilsbøll, T, Knop, FK, Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab 101 (2016), 3002–3009.
30. 30 Orskov, C, Wettergren, A, Holst, J, Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31 (1996), 665–670.
31. 31 Holst, J, The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007), 1409–1439.
32. 32 Vedtofte, L, Bodvarsdottir, TB, Gotfredsen, CF, Karlsen, AE, Knudsen, LB, Heller, RS, Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regul Pept 160 (2010), 106–114.
33. 33 Knop, F, Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. Am J Physiol Endocrinol Metab 299 (2010), E10–E13.
34. 34 Katsuma, S, Hirasawa, A, Tsujimoto, G, Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329 (2005), 386–390.
35. 35 Harach, T, Pols, TWH, Nomura, M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2 (2012), 2–8.
36. 36 Hansen, M, Scheltema, MJ, Sonne, DP, et al. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. Diabetes Obes Metab 18 (2016), 571–580.
37. 37 Ullmer, C, Alvarez Sanchez, R, Sprecher, U, et al. Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release. Br J Pharmacol 169 (2013), 671–684.
38. 38 Duan, H, Ning, M, Chen, X, et al. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J Med Chem 55 (2012), 10475–10489.
39. 39 Herbert, MR, Siegel, DL, Staszewski, L, et al. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett 20 (2010), 5718–5721.
40. 40 Gomez, G, Lluis, F, Ishizuka, J, et al. Bile enhances release of insulin: an incretin-mediated effect. Surgery 102 (1987), 195–199.
41. 41 Potthoff, MJ, Potts, A, He, T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 304 (2013), G37–G80.
42. 42 Wu, T, Bound, MJ, Standfield, SD, et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab 15 (2013), 474–477.
43. 43 Adrian, TE, Gariballa, S, Parekh, KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55 (2012), 2343–2347.
44. 44 Wu, T, Bound, MJ, Standfield, SD, Jones, KL, Horowitz, M, Rayner, CK, Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 98 (2013), E718–E722.
45. 45 Murakami, M, Une, N, Nishizawa, M, Suzuki, S, Ito, H, Horiuchi, T, Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus, 2, 2013, 20.
46. 46 Hodge, R, Lin, J, Vasist, L, EP, G, Bowers, G, Nunez, D, Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2 (2013), 213–222.
47. 47 Budzik, BW, Evans, KA, Wisnoski, DD, et al. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists. Bioorg Med Chem Lett 20 (2010), 1363–1367.
48. 48 Laferrère, B, Heshka, S, Wang, K, et al. Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007), 1709–1716.
49. 49 le Roux, CW, Welbourn, R, Werling, M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 (2007), 780–785.
50. 50 Morínigo, R, Moizé, V, Musri, M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91 (2006), 1735–1740.
51. 51 Salehi, M, Prigeon, RL, D'Alessio, DA, Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 60 (2011), 2308–2314.
52. 52 Glicksman, C, Pournaras, DJ, Wright, M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 47 (2010), 482–484.
53. 53 Ahmad, NN, Pfalzer, A, Kaplan, LM, Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 37 (2013), 1553–1559.
54. 54 Patti, ME, Houten, SM, Bianco, AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17 (2009), 1671–1677.
55. 55 Jørgensen, NB, Dirksen, C, Bojsen-Moller, KN, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 100 (2015), E396–E406.
56. 56 Bays, H, Colesevelam HCI added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from three clinical studies. Endocr Pract 17 (2011), 933–938.
57. 57 Chen, L, Yao, X, Young, A, et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab 302 (2012), E68–E76.
58. 58 Goldberg, RB, Fonseca, Va, Truitt, KE, Jones, MR, Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168 (2008), 1531–1540.
59. 59 Beysen, C, Murphy, EJ, Deines, K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55 (2012), 432–442.
60. 60 Rudling, M, Camilleri, M, Graffner, H, Holst, JJ, Rikner, L, Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord, 15, 2015, 75.
61. 61 Meyer-Gerspach, AC, Steinert, RE, Keller, S, Malarski, A, Schulte, FH, Beglinger, C, Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J Clin Endocrinol Metab 98 (2013), 3351–3358.
62. 62 Watanabe, M, Morimoto, K, Houten, SM, et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS One, 7, 2012, e38286.
63. 63 Vassileva, G, Hu, W, Hoos, L, et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol 205 (2010), 225–232.
64. 64 Pournaras, DJ, Glicksman, C, Vincent, RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153 (2012), 3613–3619.
65. 65 Bueter, M, Löwenstein, C, Olbers, T, et al. Gastric bypass increases energy expenditure in rats. Gastroenterology 138 (2010), 1845–1853.
66. 66 Stylopoulos, N, Hoppin, AG, Kaplan, LM, Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) 17 (2009), 1839–1847.
67. 67 Nestoridi, E, Kvas, S, Kucharczyk, J, Stylopoulos, N, Resting energy expenditure and energetic cost of feeding are augmented after Roux-en-Y gastric bypass in obese mice. Endocrinology 153 (2012), 2234–2244.
68. 68 Broeders, EPM, Nascimento, EBM, Havekes, B, et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 22 (2015), 418–426.
69. 69 Langeveld, M, Tan, CY, Soeters, M, et al. Mild cold effects on hunger, food intake, satiety and skin temperature in humans. Endocr Connect 5 (2016), 65–73.
70. 70 Ockenga, J, Valentini, L, Schuetz, T, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab 97 (2012), 535–542.
71. 71 Brufau, G, Bahr, MJ, Staels, B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond), 7, 2010, 73.
72. 72 Benedetti, G, Mingrone, G, Marcoccia, S, et al. Body composition and energy expenditure after weight loss following bariatric surgery. J Am Coll Nutr 9 (2000), 270–274.
73. 73 Kohli, R, Bradley, D, Setchell, KD, Eagon, JC, Abumrad, N, Klein, S, Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98 (2013), E708–E712.
74. 74 Werling, M, Olbers, T, Fandriks, L, et al. Increased postprandial energy expenditure may explain superior long term weight loss after Roux-en-Y gastric bypass compared to vertical banded gastroplasty. PLoS One, 8, 2013, e60280.
75. 75 Eggink, HM, Soeters, MR, Pols, TW, TGR5 ligands as potential therapeutics in inflammatory diseases. Int J Interfer Cytokine Med Res 6 (2014), 27–38.
76. 76 Pols, TW, TGR5 in inflammation and cardiovascular disease. Biochem Soc Trans 42 (2014), 244–249.
77. 77 Fiorucci, S, Cipriani, S, Mencarelli, A, Renga, B, Distrutti, E, Baldelli, F, Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 10 (2010), 579–595.
78. 78 Wang, YD, Chen, WD, Yu, D, Forman, BM, Huang, W, The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54 (2011), 1421–1432.
79. 79 Péan, N, Doignon, I, Garcin, I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 58 (2013), 1451–1460.
80. 80 Lou, G, Ma, X, Fu, X, et al. GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells. PLoS One 9 (2014), 1–10.
81. 81 Haselow, K, Bode, JG, Wammers, M, et al. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J Leukoc Biol 94 (2013), 1253–1264.
82. 82 Hogenauer, K, Arista, L, Schmiedeberg, N, et al. G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype. J Med Chem 57 (2014), 10343–10354.
83. 83 Ichikawa, R, Takayama, T, Yoneno, K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 136 (2012), 153–162.
84. 84 Mobraten, K, Haugbro, T, Karlstrom, E, Kleiveland, CR, Lea, T, Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line. J Recept Signal Transduct Res 35 (2015), 402–409.
85. 85 Perino, A, Pols, TW, Nomura, M, Stein, S, Pellicciari, R, Schoonjans, K, TGR5 reduces macrophage migration through mTOR-induced C/EBPbeta differential translation. J Clin Invest 124 (2014), 5424–5436.
86. 86 Cipriani, S, Mencarelli, A, Chini, MG, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One, 6, 2011, e25637.
87. 87 Yoneno, K, Hisamatsu, T, Shimamura, K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 139 (2013), 19–29.
88. 88 Hov, JR, Keitel, V, Schrumpf, E, Häussinger, D, Karlsen, TH, TGR5 sequence variation in primary sclerosing cholangitis. Dig Dis 29 (2011), 78–84.
89. 89 Nappo, F, Esposito, K, Cioffi, M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39 (2002), 1145–1150.
90. 90 Aljada, A, Mohanty, P, Ghanim, H, Increase in intranuclear nuclear factor κB and decrease in inhibitor κB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 79 (2004), 682–690.
91. 91 Dickinson, S, Hancock, DP, Petocz, P, Ceriello, A, Brand-Miller, J, High-glycemic index carbohydrate increases nuclear factor-kB activation in mononuclear cells of young, lean healthy subjects. Am J Clin Nutr 87 (2008), 1188–1193.
92. 92 Patel, C, Ghanim, H, Ravishankar, S, et al. Prolonged reactive oxygen species generation and nuclear factor-kB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab 92 (2007), 4476–4479.
93. 93 Ghanim, H, Abuaysheh, S, Sia, CL, Korzeniewski, K, Chaudhuri, A, Fernandez-Real, JM, Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal. Diabetes Care 32 (2009), 2281–2287.
94. 94 Clemente-Postigo, M, Queipo-Ortuño, MI, Murri, M, et al. Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patients. J Lipid Res 53 (2012), 973–978.
95. 95 Li, T, Holmstrom, SR, Kir, S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 25 (2011), 1066–1071.
96. 96 Briere, DA, Ruan, X, Cheng, CC, et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS One 10 (2015), 1–17.
97. 97 Fryer, RM, Ng, KJ, Nodop Mazurek, SG, et al. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism. J Pharmacol Exp Ther 348 (2014), 421–431.
98. 98 Yasuda, H, Hirata, S, Inoue, K, Mashima, H, Ohnishi, H, Yoshiba, M, Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 354 (2007), 154–159.
99. 99 Casaburi, I, Avena, P, Lanzino, M, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 11 (2012), 2699–2710.
100. 100 Hong, J, Behar, J, Wands, J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 59 (2010), 170–180.
101. 101 Cao, W, Tian, W, Hong, J, et al. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 304 (2013), G322–G327.